tert-butyl N-[[methyl(phenyl)carbamoyl]methyl]carbamate | 403860-27-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[[methyl(phenyl)carbamoyl]methyl]carbamate
• 英文别名: Boc-Gly-N(Me)-Ph；N-methyl-N-phenyl-2-(tert-butoxycarbonylamino)acetamide；Tert-butyl (2-(methyl(phenyl)amino)-2-oxoethyl)carbamate；tert-butyl N-[2-(N-methylanilino)-2-oxoethyl]carbamate
• CAS: 403860-27-5
• 化学式: C₁₄H₂₀N₂O₃
• mdl: MFCD24391766
• 分子量: 264.324
• InChiKey: ALQSADWIENAYSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[[methyl(phenyl)carbamoyl]methyl]carbamate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Constrained TRPV1 agonists synthesized via silver-mediated intramolecular azo-methine ylide cycloaddition of α-iminoamides

  摘要：

  As part of an effort to identify agonists of TRPV1, a peripheral sensory nerve ion channel, high throughput screening of the NIH Small Molecule Repository (SMR) collection identified MLS002174161, a pentacyclic benzodiazepine. A synthesis effort was initiated that ultimately afforded racemic seco analogs 12 of the SMR compound via a silver mediated intramolecular [3+2] cycloaddition of an azo-methine ylide generated from alpha-iminoamides 11. The cycloaddition set four contiguous stereocenters and, in some cases, also spontaneously afforded imides 13 from 12. The synthesis of compounds 12, the features that facilitated the conversion of 12-13, and their partial agonist activity against TRPV1 are discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.061
• 作为产物：
  描述：

  N-(t-butoxycarbonyl)glycyl i-butyl carbonate 、 N-甲基苯胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以1.39 g的产率得到tert-butyl N-[[methyl(phenyl)carbamoyl]methyl]carbamate
  参考文献：
  名称：

  对含有阿片类药效团 Dmt-Tic 的先导化合物的进一步研究。

  摘要：

  一些含有 Dmt-Tic 药效团的参考阿片类药物，尤其是 δ 激动剂 H-Dmt-Tic-Gly-NH-Ph (1) 和 H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid (4) ) (UFP-512) 评估了用天冬氨酸取代 Gly 的影响、其手性，以及 -NH-Ph 和 N(1)H-Bid 氢在 δ 激动诱导中的重要性。结果提供以下结论： (i) Asp 通过降低 mu 亲和力增加 delta 选择性；(ii) -NH-Ph 和 N(1)H-Bid 氮甲基化将 delta 激动剂转化为 delta 拮抗剂；(iii)在δ激动剂H-Dmt-Tic-Gly-NH-Ph中用L-Asp/D-Asp取代Gly得到δ拮抗剂；δ 激动剂 H-Dmt-Tic-NH-CH2-Bid 中的相同取代产生更具选择性的激动剂 H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid 和 H-Dmt-Tic-NH

  DOI：

  10.1021/jm800587e

文献信息

• Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
  申请人：——

  公开号：US20030232875A1

  公开（公告）日：2003-12-18

  Heterocyclic amide derivatives, of formula (I): wherein —X-Y-Z- is selected from —S—CR 4 ═CR 5 —, —CR 4 ═CR 5 —S—, —O—CR 4 ═CR 5 —, —CR 4 ═CR 5 —O—, —N═CR 4 —S—, —S—CR 4 ═N—, —NR 6 —CR 4 ═CR 5 — and —CR 4 ═CR 5 —NR 6 —; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; (with provisos); possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  杂环酰胺衍生物的化学式（I）：其中—X-Y-Z-选择自—S—CR4═CR5—，—CR4═CR5—S—，—O—CR4═CR5—，—CR4═CR5—O—，—N═CR4—S—，—S—CR4═N—，—NR6—CR4═CR5—和—CR4═CR5—NR6—；或其药学上可接受的盐或体内可水解酯；（附带条件）；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。
• [EN] ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS<br/>[FR] DÉRIVÉS ACÉTAMIDO EN TANT QU'INHIBITEURS DE L'ADN POLYMÉRASE THÊTA
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2020160134A1

  公开（公告）日：2020-08-06

  Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

  本文披露了某些DNA聚合酶Θ（Polθ）抑制剂的乙酰胺衍生物，其化学式为（I）。同时，还披露了包括这些化合物的药物组合物以及治疗可通过抑制Polθ来治疗的疾病的方法，如癌症，包括同源重组（HR）缺陷性癌症。
• Design and synthesis of novel diamide derivatives of glycine as antihyperglycemic agents
  作者：Radhika Sharma、Shubhangi S. Soman

  DOI：10.1080/00397911.2016.1203435

  日期：2016.8.2

  in the market contain a proline mimetic active pharmacophore. Herein, we report the design, synthesis, and preliminary evaluation of a series of novel diamide derivatives of glycine, devoid of the proline mimic, for the treatment of T2D. As predicted from in silico studies, the diamide derivatives of glycine exhibited comparable DPP-4 inhibition with the standard as confirmed by the preliminary in vitro

  摘要 DPP-4 抑制是治疗 2 型糖尿病 (T2D) 的最广泛探索的方法之一。市场上的大多数 DPP-4 抑制剂都含有模拟脯氨酸的活性药效团。在此，我们报告了一系列新型甘氨酸二酰胺衍生物的设计、合成和初步评估，不含脯氨酸模拟物，用于治疗 T2D。正如计算机模拟研究所预测的那样，甘氨酸的二酰胺衍生物表现出与标准品相当的 DPP-4 抑制作用，正如初步体外研究所证实的那样。发现化合物 6b 是该系列合成的所有分子中最有效的 (IC50 94.82 nM) DPP-4 抑制剂。图形概要
• Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Tung S. Jay

  公开号：US20050038099A1

  公开（公告）日：2005-02-17

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明涉及一种是Bradykinin B1受体拮抗剂的化合物，可用于治疗哺乳动物中由Bradykinin B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还会表现出持续时间的增加。
• 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
  申请人：Tung S. Jay

  公开号：US20070161633A1

  公开（公告）日：2007-07-12

  Disclosed are compounds of formulae (I) and (II) that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.

  本发明涉及式(I)和(II)的化合物，它们是布雷地奎宁B1受体拮抗剂，可用于治疗哺乳动物中由布雷地奎宁B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中Z从O、S和NH中选择；公式(III)中的Q和其他取代基如权利要求1所定义。其中某些化合物表现出增强的效力，并且预计还会表现出延长作用时间。